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Abstract
Background
Most patients with cystic fibrosis (CF) suffer from pancreatic insufficiency, leading to fat mal-
absorption, malnutrition and abdominal discomfort. Until recently, no specific tool was avail-
able for assessing gastro-intestinal related quality of life (GI QOL) in patients with CF. As the
Horizon2020 project MyCyFAPP aims to improve GI QOL by using a newly designed mobile
application, a sensitive and reliable outcome measure was needed. We aimed to study the
applicability of the existing child-specific Pediatric Quality of Life Inventory, Gastrointestinal
Symptoms Scales and Module (PedsQL GI) in children with CF.
Methods
A multicenter, prospective observational study was performed in 6 European centers to vali-
date the PedsQL GI in children with CF during 3 months.
Results
In total, 248 children and their parents were included. Within-patient variability of PedsQL GI
was low (24.11), and there was reasonable agreement between children and parents (ICC
0.681). Nine of 14 subscales were informative (no ceiling effect). The PedsQL GI and the
median scores for 4 subscales were significantly lower in patients compared to healthy con-
trols. Positive associations were found between PedsQL GI and age (OR = 1.044, p =
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0.004) and between PedsQL GI and BMI z-score (OR = 1.127, p = 0.036). PedsQL GI corre-
lated with most CFQ-R subscales (r 0.268 to 0.623) and with a Visual Analogue Scale (r =
0.20).
Conclusions
PedsQL GI is a valid and applicable instrument to assess GI QOL in children with CF. Future
research efforts should examine the responsiveness of the CF PedsQL GI to change in the
context of clinical interventions and trials.
Introduction
Cystic Fibrosis (CF) is the most common life-threatening autosomal inherited disease in
Europe where currently over 44,000 cases of CF are registered [1]. It is a multisystemic disor-
der with main involvement of the respiratory and gastro-intestinal tract. Pancreatic insuffi-
ciency (PI) leads to steatorrhea, abdominal distension and/or discomfort, flatulence,
constipation and poor weight gain. Treatment consists of pancreatic enzyme replacement ther-
apy (PERT), high caloric diet and supplementation with fat soluble vitamins [2–3]. In CF,
nutritional status has a major impact on the progression of pulmonary disease [4]. Particular
attention is needed to prevent an imbalance between energy losses (due to PI), increased
energy needs (due to pulmonary disease) and usual energy intake [2,5].
Despite treatment with PERT, close nutritional follow-up and multidisciplinary support,
residual fat malabsorption occurs in a considerable number of patients with CF [6] resulting in
nutritional deficiencies [7] and abdominal symptoms [8]. Up to now, there was hardly any evi-
dence about the optimal dose of PERT needed nor how to adapt this to individual patient’s
needs [2,9].
The MyCyFAPP project aims to develop and validate a mobile application (APP) to opti-
mize and personalize the intake of PERT [10]. An algorithm, integrated in the APP, was devel-
oped to determine the optimal PERT dose needed per meal, based on in vitro data of food
digestion [11–12]. In the final phase of the project, a European multicentre prospective clinical
trial was planned to assess the impact of the use of the APP on patient outcomes. Quality of life
(QOL) assessment as a Patient Reported Outcome (PRO) is a widely accepted clinical endpoint
in clinical trials [13–14]. Quality of life (QOL) is an overarching term, reflecting the expecta-
tion of an individual of the quality of various domains in life. Quality of life has been widely
studied, mostly using self-reports. As QOL is a very relevant outcome from a patient-perspec-
tive, gastro-intestinal related QOL (GI QOL) was chosen as the primary outcome for the
MyCyFAPP trial.
A literature search resulted in the identification of two relevant existing QOL question-
naires. The first is the CF-specific QOL questionnaire, the CFQ-R [15–17], to be used for chil-
dren and their parents from 6 years onwards. Thus far, only the respiratory domain of this
scale has been approved as endpoint by the FDA [12] and was used as a primary outcome
parameter in only a few clinical trials [18–19]. The child version of CFQ-R includes a domain
assessing abdominal quality of life (digestion), but this scale includes only 7 items and does not
cover all relevant GI aspects in CF; it was therefore considered not suitable as a primary out-
come parameter in the MyCyFAPP project. Very recently, the abdominal domain was
expanded for the adults and teen versions only [20], so it is not applicable for the current
project.
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The second scale is the Pediatric Quality of Life Inventory, Gastrointestinal Symptoms
Scales and Module (PedsQL GI) [21]. It is a generic symptom measurement instrument, con-
sisting of 14 GI related subscales. It is feasible in (young) children with abdominal symptoms,
can discriminate between health and disease and has been validated in patients with several
gastrointestinal diseases (i.e. Crohn’s disease, gastroesophageal reflux disease and functional
gastro-intestinal disorders) [22–23]. Previously, it was shown that the subscales have a high
internal consistency [22]. The PedsQL GI, however, has not been validated for use in children
with CF yet.
Because of its proven usability in chronic GI illnesses, the PedsQL GI was selected as a can-
didate measure to be used in the MyCyFAPP trial. The present study aims to investigate the
psychometric characteristics of the PedsQL GI and assess the usability of the PedsQL GI in
children with CF. The aim was to study the natural variability of the PedsQL GI subscales, the
relation to validated QOL scales (CFQ-R, Visual Analogue Scale (VAS)), ceiling and floor
effects, agreement between children and parents, correlation with clinical data (e.g. age,
BMI,. . .) and finally identify the most informative subscales to be used in the MyCyFAPP proj-
ect. Therefore, a multicenter, prospective observational study was performed with evaluation
of PedsQL GI, CFQ-R and VAS at 2 time points with a clinically stable interval of 3 months.
Materials and methods
Study population
A 3-month observational, multicenter study was performed in stable children with CF 24
months to 18 years of age, all having PI (stool elastase < 200 mcg/g stool) and treated with
PERT. A three-month follow up time period was chosen as convenience for the patients, as
this would coincide with regular outpatient clinic.
The children were recruited in the 6 European CF centers participating in the MyCyFAPP
project (Lisbon, Madrid, Milan, Leuven, Rotterdam, Valencia). The diagnosis of CF had been
confirmed by a sweat chloride concentration� 60 mEq/L and/or the presence of 2 disease-
causing mutations in the CFTR gene. Patients and their parents were informed about the study
during the outpatient clinic.
As the majority of children in each center would be included in the trial, a control group
could not be established. The results from healthy controls were used from published data in a
US population [23].
Exclusion criteria were: an acute infection associated with decreased appetite or fever, acute
abdominal pain necessitating an intervention at the time of inclusion, physical findings that
would compromise the safety of the participant or the quality of the study data as determined
by the investigators, investigational drug use within 30 days prior to inclusion or recent start
on CFTR modulator therapy within 3 months prior to inclusion.
The study was approved by the ethics committees of all 6 participating centers (University
Hospital Gasthuisberg, Leuven; Instituto de Investigacio´n Sanitaria La Fe, Valencia; Ospedale
Maggiore Policlinico, Milan; Hospital Universitario Ramo´n y Cajal, Madrid; Erasmus Medical
Center, Sophia Children’s Hospital, Rotterdam). Parents signed an informed consent form for
their own participation and for the participation of their child; in accordance with local regula-
tions, adolescents aged 12 years and older signed an assent or consent form.
Questionnaires
Patients filled out the age-appropriate versions of the PedsQL GI [24], CFQ-R [16] and a
Visual Analogue Scale (VAS) at baseline (M0) and after 3 months (M3) during regular outpa-
tient clinics. Parents and children were asked to fill out the questionnaires independently.
Validation of PedsQL GI in children with cystic fibrosis and their parents
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The PedsQL GI is a symptom-specific questionnaire to measure gastrointestinal symptoms
in children 2–18 years [21–23]. It consists of 74 questions in 14 subdomains (including stom-
ach pain, constipation, worries about bowel movement,. . .). The feasibility is high (easy to fill
out with only 1,69% missing for children, 1,84% missing for adults) and the estimated comple-
tion time is 15 minutes. Normal values are available. The subscales have a high internal consis-
tency (reliability of all subscores > 0,70 and>0,90 for total score) and discriminate between
health and disease. The subscales can be used individually and for each subscale the minimal
clinical significant change is known. A higher score indicates better QOL. PedsQL GI is abnor-
mal in several disorders (Crohn’s disease, constipation,. . .).
The CFQ-R evaluates general quality of life in patients with cystic fibrosis from the age of 6
years in several subdomains (including physical functioning, treatment burden, respiratory
symptoms,. . .). The subscales have a high internal consistency, discriminate between health
and disease and a good construct validity was shown [16].
The VAS consists of a linear scale to answer the question ‘How is your health state today?’
from 0 to 100%. It is an easy and fast to use tool that is well validated and has an added value
on the evaluation of generic QOL.
A parent report was included for all age groups for the PedsQL GI and the VAS, and for the
CFQ-R for children aged 6–14. For children < 4 years old, only a parent report for the PedsQL
and VAS was included. The CFQ-R has child versions for children older than 6 years. See S1
Table for an overview of the combination of the different scales used. The same versions were
used at both study visits, independently from changing age category.
In preparation of this study, we paid the rights to use the PedsQL GI, in consultation with
Dr. Varni, the intellectual owner of the PedsQL GI. As contractually required, and following
previous research using PedsQL scales, the PedsQL GI was translated forward and backward
into Dutch, Flemish, Italian, Portuguese and Spanish, and the translations were validated by
interviewing a minimum of 5 test patients/parents per version to assess comprehensibility, rel-
evance as well as construct and content validity of the translations. This procedure was in
accordance with the instructions from Dr. Varni.
A 3 or 5-point response scale is used for scoring of all individual items of the PedsQL GI
and it’s subscores. Items are reverse-scored and linearly transformed to a 0–100 scale so that
100% corresponds to no symptoms and 0% to the presence of severe symptoms in that
domain.
Clinical data
Spirometry, height, weight and BMI were assessed at M0 and M3. Spirometry data were calcu-
lated according to the GLI references [25], height, weight and BMI according to the CDC ref-
erences [26]. The daily dose of PERT (LU/kg/day) used was registered at M0 and M3.
The study started in October 2016 and finished in May 2017.
Statistical analysis
Patient characteristics. Clinical data were summarized by median scores (1st, 3rd Q) in
the case of continuous variables and by relative and absolute frequencies in the case of categor-
ical variables.
Data on PedsQL GI in patients with CF were compared to those published for healthy con-
trols, using linear regression [23]. Factor analyses could not be performed due to the small
sample size of participants in each age group. Cronbach alpha was used to determine internal
consistency of scales and subscales: scales with a value >0.7 are recommended for comparing
Validation of PedsQL GI in children with cystic fibrosis and their parents
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patient groups whereas those with a value>0.90 are recommended for comparison within
individuals [27].
The anticipated differences (effect sizes) between patients with CF and healthy controls
were estimated by taking the difference between the healthy sample means and the CF sample
means, divided by the pooled SD (Cohen’s D). Effect sizes for differences in means are desig-
nated as small (0.20), medium (0.50), and large (0.80). The minimal important difference
(MID) was calculated as the standard error of the measurement (SEM) divided by the square
root of 1-Cronbach alpha [27].
PedsQL GI natural variability. Intraclass Correlation Coefficient (ICC) and confidence
intervals (CI) were calculated to assess the reliability between patients (between patient’s vari-
ability) and parents, as well as between months (within patient variability). Taking into
account the ratio between subject variability and total variability, the ICC provides an index of
absolute agreement by means of one-way ANOVA. ICC values below 0.5, between 0.5 and
0.75, between 0.75 and 0.9, and greater than 0.90 are indicative of poor, moderate, good, and
excellent reliability, respectively [28].
Association between PedsQL GI and patient characteristics. Beta mixed regression was
performed to study the association between PedsQL GI and several covariates that were
selected according to the expert knowledge: Age, BMI z-score, FEV1 z-score, gender, dose of
PERT and time (change between first and second evaluation).
To select subscales of importance for use in the clinical trial, we used the feedback from the
interviews of patients/parents (see above) and we set a 95% cut-off: subscales with a median
value >95% demonstrated a ceiling effect and are thus unlikely to be informative to study an
intervention.
Correlation between PedsQL GI and CFQ-R, VAS. The Spearman correlation coeffi-
cient was calculated between PedsQL GI and each CFQ-R’s subscale score. The same analyses
were performed with the CF PedsQL GI.
The validation process included data collection at baseline and 3-months. Pooled data were
used to calculate the correlation between PedsQL GI and CFQ-R as well as the correlation
between PedsQL GI and VAS, both for patients as for parents.
CF PedsQL GI
The shortened, CF specific version of PedsQL GI (CF PedsQL GI) was defined as the mean
score of all informative subscores i.e. those with a median result�95%.
All analyses were performed using R software (version 3.4.1.) and packages ICC (version
2.3.0), MBESS (version 4.3.0), glmmADMB (version 0.8.3.3) and clickR (0.4.04).
Results
Patient characteristics
Two hundred and forty-eight children were included in the study at M0 (Table 1), 239 com-
pleted the second questionnaire at M3. At least one parent was included per child. Forty-eight
children were between 2 and 4 years old and thus could not fill in a child version of the ques-
tionnaire themselves, so 200 patient questionnaires were collected at M0.
The subscales without ceiling effect are: ‘Stomach pain and hurt’, ‘Stomach discomfort
when eating’, ‘Heartburn and Reflux’, ‘Gas and Bloating’, ‘Constipation’, ‘Diarrhoea’, ‘Worry
about Stomach Aches’, ‘Medicines’, and ‘Communication’ (Table 2). These subscales are all
clinically relevant for patients with CF and were thus included in the ‘CF PedsQL GI’. In the
parents’ questionnaires, the same subscales had mean values�95% (S2 Table).
Validation of PedsQL GI in children with cystic fibrosis and their parents
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Natural variability
The ICC between M0 and M3 measurement was moderate to good for most of the subscales,
which implies reasonable reproducibility (Table 3). ICCs between children and their parents
were also moderate for most subscales, indicating that both children and their parents perceive
the child’s symptom profiles similarly. The within-patient variability (24.11) was much lower
than the between-patients variability (77.75).
Association between PedsQL GI and patient characteristics
Beta mixed regression was performed to study the association between PedsQL GI and several
covariates: age, BMI z-score, FEV1 z-score, gender and time (first or second visit) (Table 4).
Because FEV1 and BMI were not independent, FEV1 was discarded from the model. There was
a positive association between PedsQL GI and BMI z-score (OR 1,127, 95% CI 1,008–1,261,
p = 0.036) as well as age (OR 1,044, 95% CI 1,014–1,076, p = 0.004). (Fig 1). There was no asso-
ciation between PedsQL GI and gender, time and FEV1 z-score. Using height z-score instead
of BMI z-score, we didn’t detect a significant difference (OR 1.002, 95% CI 0.916–1.096,
p = 0.97). There was no association between PedsQL GI and total PERT dose (OR 0.877, 95%
CI 0.754–1.019, p = 0.086).
Table 1. Patient characteristics.
Variable n = 248
Mean (SD)
Age (y) 9.21 (5.3, 13.58)
PERT intake (LU/day) 187 500 (105 000, 280 000)
PERT intake (LU/kg/day) 6 233.97 (3 926.11, 9 465.22)
Weight (CDC z-score) -0.23 (-0.91, 0.26)
Height (CDC z-score)
BMI (CDC z-score)
-0.12 (-0.86, 0.49)
-0.29 (-0.92, 0.27)
FVC z-score -0.49 (-1.48, 0.45)
FEV1 z-score -1.02 (-2.3, 0.16)
FEV1/FVC z-score -0.95 (-1.82, -0.26)
FEF25-75 z-score -1.19 (-2.57, -0.06)
Girl (n, %) 116 (46.8%)
CF center (n, %)
Lisbon 42 (16.9%)
Rotterdam 29 (11.7%)
Valencia 41 (16.5%)
Leuven 42 (16.9%)
Madrid 32 (12.9%)
Milan 62 (25%)
Abbreviations: y = year, LU = lipase units, CDC = Center for Disease Control, BMI = body mass index, FVC = forced
vital capacity, FEV1 = forced expiratory volume at 1 second, FEF25-75 = forced expiratory flow between 25–75% of the
pulmonary volumeThe median total child-reported PedsQL GI at baseline was 85.5 (IQR 78.6–92.6) and was
significantly lower than in healthy controls (median 89.8, p 0.04) (Table 2) [23]. Median values were significantly
lower compared to healthy controls for 4 subscales: ‘Diarrhoea’, ‘Constipation’, ‘Gas and Bloating’ and ‘Worry about
stomach aches’. For one subscale, ‘Blood in bowel movement’, patients with CF had higher (better) values than
healthy controls. Similar results were obtained from parents (S2 Table). The internal consistency was good for most
subscales. Data for age subgroups are presented in S3 Table and S4 Table and show only small differences due to
lower patient numbers.
https://doi.org/10.1371/journal.pone.0225004.t001
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Correlation between PedsQL GI and CFQ-R, VAS
There was a significant, but weak correlation between PedsQL GI and VAS (rho = 0.20,
p<0.001). Most of the subscales of CFQ-R correlated weakly, but significantly with PedsQL GI
for each patient age group (S5 Table).
Table 2. Results for the total PedsQL GI in children with CF, obtained in our study at baseline, compared to published healthy controls [23].
Healthy Controls Patients with CF n = 248 Cronbach α MID �� Linear Regression Effect Sizes
Median (1st, 3rd Q.) Median (1st, 3rd Q.) Difference [CI 95%]; p-value
Total PedsQL GI (%) 89.8 (79.14, 98.41) 85.5 (78.55, 92.6) 0.94 2.33 -2.15 [-4.22, -0.08] p = 0.04� 0.215
Stomach_Pain (%) 81.6 (67.04, 93.95) 83.3 (73.95, 95.8) 0.84 7.42 0.91 [-2.24, 4.07] p = 0.57 -0.05
Stomach_Discomfort (%) 93.29 (79.68, 100) 95 (85, 100) 0.72 8.15 1.89 [-0.79, 4.56] p = 0.16 -0.125
Food_Drink_Limits (%) 94.14 (80.09, 100) 95.8 (83.3, 100) 0.80 7.33 2.63 [-0.19, 5.46] p = 0.07 -0.16
Trouble_Swallowing (%) 97.28 (89.26, 100) 100 (91.7, 100) 0.49 8.35 1.78 [-0.09, 3.65] p = 0.06 -0.15
Heartburn_reflux (%) 92.49 (81, 100) 87.5 (75, 93.8) 0.52 9.37 0.5 [-1.77, 2.77] p = 0.66 -0.04
Nausea_vomiting (%) 92.49 (81, 100) 100 (81.2, 100) 0.79 7.32 2.09 [-0.52, 4.70] p = 0.12 -0.13
Gas_and_bloating (%) 85.57 (70.47, 98.73) 75 (64.3, 89.3) 0.81 8.65 -9.36 [-12.76, -5.95] p < 0.001� 0.47
Constipation (%) 90.09 (74.88, 100) 85.7 (73.2, 94.6) 0.89 4.78 -3.92 [-6.56, -1.27] p = 0.004� 0.26
Blood bowel movement (%) 98.15 (88.24, 100) 100 (100, 100) 0.64 4.47 4.74 [3.21, 6.28] p < 0.001� -0.54
Diarrhea (%) 97.35 (87.52, 100) 85.7 (78.6, 100) 0.76 6.37 -4.68 [-6.79, -2.57] p < 0.001� 0.34
Worry_bowel_movements (%) 97.79 (85.1, 100) 100 (85, 100) 0.73 7.59 -0.49 [-2.81, 1.82] p = 0.67 0.03
Worry_stomach_aches (%) 92.89 (80.18, 100) 87.5 (62.5, 100) 0.73 11.25 -5.19 [-8.51, -1.87] p = 0.002� 0.25
Medicines (%) 87.5 (68.8, 93.8) 0.55 11.84
Communication (%) 90 (65, 100) 0.79 10.54
Note that no data were available in literature for the subscales ‘Medicines’ and ‘Communication’. Subscales with a median score�95% in patients with CF are marked in
bold. Significant differences between patients with CF and healthy controls are marked with �.
Abbreviations: MID minimal important difference
https://doi.org/10.1371/journal.pone.0225004.t002
Table 3. Intraclass correlation coefficients for the total score and subscales of the PedsQL GI.
Subscale Intraclass Correlation
Coefficient Between
Measurements (M0-M3)
Children
Intraclass Correlation
Coefficient Between
Measurement (M0-M3)
Parents
Intraclass Correlation
Coefficient Between Children
and Parents Measurements
(M0)
Intraclass Correlation
Coefficient Between Children
and Parents Measurements
(M3)
ICC [CI 95%] ICC [CI 95%] ICC [CI 95%] ICC [CI 95%]
PedsQL GI Total Score 0.764 [0.698, 0.829] 0.768 [0.711, 0.826] 0.681 [0.599, 0.763] 0.671 [0.589, 0.754]
Stomach Pain and Hurt 0.59 [0.495, 0.686] 0.671 [0.599, 0.743] 0.538 [0.439, 0.637] 0.665 [0.585, 0.746]
Stomach Discomfort When Eating 0.611 [0.519, 0.703] 0.694 [0.626, 0.761] 0.566 [0.472, 0.66] 0.627 [0.539, 0.714]
Food and Drink Limits 0.57 [0.47, 0.669] 0.558 [0.467, 0.648] 0.597 [0.507, 0.687] 0.399 [0.276, 0.522]
Trouble Swallowing 0.486 [0.374, 0.599] 0.66 [0.586, 0.733] 0.351 [0.228, 0.474] 0.43 [0.311, 0.549]
Heartburn and Reflux 0.529 [0.424, 0.635] 0.663 [0.59, 0.736] 0.527 [0.427, 0.628] 0.528 [0.424, 0.632]
Nausea and Vomiting 0.608 [0.515, 0.701] 0.664 [0.592, 0.737] 0.645 [0.564, 0.725] 0.62 [0.531, 0.709]
Gas and Bloating 0.665 [0.583, 0.748] 0.68 [0.609, 0.75] 0.614 [0.527, 0.701] 0.545 [0.442, 0.647]
Constipation 0.71 [0.636, 0.783] 0.761 [0.705, 0.817] 0.646 [0.563, 0.728] 0.563 [0.462, 0.663]
Blood bowel movement 0.143 [-0.005, 0.292] 0.469 [0.367, 0.571] 0.424 [0.309, 0.539] 0.169 [0.022, 0.316]
Diarrhea 0.646 [0.56, 0.731] 0.7 [0.633, 0.766] 0.491 [0.385, 0.597] 0.57 [0.473, 0.668]
Worry about bowel movements 0.754 [0.692, 0.817] 0.726 [0.665, 0.788] 0.554 [0.458, 0.651] 0.401 [0.277, 0.524]
Worry about Stomach Aches 0.47 [0.355, 0.585] 0.568 [0.48, 0.657] 0.341 [0.216, 0.466] 0.482 [0.37, 0.593]
Medicines 0.692 [0.616, 0.769] 0.721 [0.658, 0.783] 0.584 [0.493, 0.676] 0.482 [0.37, 0.594]
Communication 0.7 [0.626, 0.775] 0.658 [0.584 0.733] 0.291 [0.16, 0.422] 0.409 [0.287, 0.531]
https://doi.org/10.1371/journal.pone.0225004.t003
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CF PedsQL GI
Table 5 demonstrates the results for the CF PedsQL GI for patients and controls and their
parents’ scores. The CF PedsQL GI correlated highly with the total PedsQL GI (r = 0.93,
p< 0.001) (S1 Fig).
Internal consistency of the CF PEDsQL, and most subscales of the CF PedsQL GI was high
(Tables 2 and 5).
Discussion
We studied the psychometric properties, the validity and applicability of the existing PedsQL
GI Module as measurement instrument for use in children with CF and their parents.
We confirm that GI QOL scores, assessed by PedsQL GI, are lower in the studied CF popu-
lation (both patients and parents) compared to (published) scores of healthy controls [23]. We
found low values (�95%) for 9 of the 14 subscales of the PedsQL GI, with most reported symp-
toms in the subscales “gas and bloating”, “stomach pain”, “constipation” and “diarrhea”. This
confirms clinical observations in children with CF [8–9]. The PedsQL GI subscales are GI
symptom specific and detailed. This makes the PedsQL GI suitable for use in CF. In addition,
scores on the subscales “worry about medicines” and “worry about communication” were low.
Table 4. Results of the Regression model to assess the association of patient characteristics on PedsQL GI.
Estimate Odd’s ratio CI 95% P-value
(Intercept) 3.008 20.247 [3.319 123.531] 0.001
Age 0.043 1.044 [1.014 1.076] 0.004
Z-score BMI 0.12 1.127 [1.008 1.261] 0.036
Gender—girl -0.158 0.854 [0.691 1.054] 0.141
Time study–m+3 0.039 1.04 [0.944 1.145] 0.43
log(pert_intake_m1) -0.132 0.877 [0.754 1.019] 0.086
https://doi.org/10.1371/journal.pone.0225004.t004
Fig 1. Association between PedsQL GI and age (1A) and BMI (1B). Abbreviation: OR = Odd’s ratio.
https://doi.org/10.1371/journal.pone.0225004.g001
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This information is relevant for the final phase of the MyCyFAPP project, in which the impact
of the use of a newly designed APP on GI QOL will be studied [10].
These results point to the important psychological burden of the GI symptoms in children
with CF and affirms concerns from patients and parents; when questioned about their priori-
ties for research in a systematic survey (James Lind Alliance project), patients put treatment
burden and GI symptoms very high on the list [29].
A ceiling effect was observed for 5/14 PedsQL GI subscales. This corresponds with the clini-
cal infrequency or absence of symptoms assessed by these subscales in patients with CF. For
example, the subscale ‘blood in bowel movement’ had a mean value of 100%, indicating no
problems at all. This corresponds with the clinical experience that bloody stools are extremely
rare in children with CF. Theoretically they can occur after bleeds from esophageal varices in
patients with the complication of liver cirrhosis and portal hypertension. However, in this con-
text hematemesis or melena is more common. In addition, systematic follow up of liver disease
and if detected, proactive treatment will prevent this complication in most patients.
The intraclass correlation between scores from patients and their parents was acceptable for
the total score and for most subscale scores. This suggests that children and their parents agree
in their perception of the symptoms and that their paired data could be compared across age
groups in clinical research.
There was no change in GI QOL during the short study period indicating an excellent test-
retest reliability. The three-month period (regular out-patient clinics) may be considered long
to examine test-retest reliability, but this period was chosen not to overburden patients. Cron-
bach alpha for the total PedsQL GI and the CF PedsQL GI was >0.90, confirming that the
scales can be used for comparison within and between individuals. There was more variability
within individual age subgroups because of lower patient numbers. However, the PedsQL GI
was designed for use among age groups with the possibility of working with all versions
together in the MyCyFAPP project.
A significant association between PedsQL GI and BMI was found. In children with CF, an
improved BMI generally reflects a better nutritional status and a correlation was expected with
higher self-reported QOL. This finding supports the construct validity of the questionnaire
and the possibility to create a CF version.
Construct validity for most subscales of the PedsQL GI was shown by the association with
established QOL measures, the CFQ-R subscales and VAS. These correlations were significant,
but weak, as anticipated, because the questionnaires assess different domains of QOL. As
expected, the strongest correlation was seen between PedsQL GI and the CFQ-R domain
‘digestion’.
In this study, we found a weak, but significant positive association between PedsQL GI and
age. This suggests that patients become less symptomatic when they grow older or ‘get used’ to
their GI symptoms. This finding demonstrates the clinical importance of care of gastro-intesti-
nal symptoms in younger children with CF.
For the first time, an existing GI-specific QOL questionnaire was examined for use in CF.
This is of high clinical and research value. Most patients with CF report abdominal symptoms,
Table 5. Results for the CF PedsQL GI.
CF PedsQL GI Median (1st, 3rd Q.) (%) Cronbach’s alpha Wilcoxon rank sum test
Patients with CF 83.30 (75, 91.20) 0.931 p < 0.001
Healthy Controls 87.66 (82.10, 91.66)
Parents of children with CF 82.65 (75.60, 90.30) 0.943 p < 0.001
Parents of healthy Controls 89.55 (85.21, 93.35)
https://doi.org/10.1371/journal.pone.0225004.t005
Validation of PedsQL GI in children with cystic fibrosis and their parents
PLOS ONE | https://doi.org/10.1371/journal.pone.0225004 December 20, 2019 9 / 14
which could not be monitored in detail until now, as the existing CFQ-R, a questionnaire on
general QOL in patients with CF, only contains 7 GI related items. Further study of the CF
PedsQL GI will assess its value as a more specific and sensitive outcome to assess GI QOL, use-
ful both in clinical settings and for research purposes: for example, trials to assess the efficacy
of CFTR modulator therapies. To date, only BMI and weight are used as nutritional outcomes
in clinical trials, but these do not reflect abdominal discomfort or abdominal symptoms.
Very recently, the JenAbdomen-CF score was developed [8]. This newly constructed ques-
tionnaire is also very detailed and aims to represent CF-specific abdominal symptoms. Reports
show correlations with findings on abdominal ultrasound [30], significant discriminative
validity and low natural variability in patients older than 6 [31]. However, there are no data on
comparison with existing questionnaires and data are scarce for the age group <6. In addition,
the potential for use as a self-report measure for children has not yet been established, which is
an important asset of the CF PedsQL GI.
We obtained repeated observational data of a large group of patients from several centers
and countries and their parents, so the data are robust. In addition, the translation to 5 differ-
ent languages is an asset.
A limitation of the study is that no study specific control group was included. The control
group used consists of North-American children without gastro-intestinal disease [21]; they
are slightly older and have a different ethnic background. For this control group, internet-
based questionnaires were used in contrast to paper forms filled out during the outpatient
clinic visit for our patients. There are no data on BMI, weight and height for the control sub-
jects. As BMI was a contributing factor in the CF group, this might induce bias. However,
since we plan to use the CF PedsQL GI for interventional studies in CF, this is of minor impor-
tance as in the MyCyFAPP trial patients will be used as their own control. Although beyond
the scope of the present study, a limitation may also be the fact that known-group differences
were not investigated (f.e. discrimination between patients with and without history of DIOS).
The interviews with patients during the detailed translation process showed that the items
of the PedsQL GI are in line with the GI symptoms patients with CF experience most fre-
quently. A limitation is that we did not perform more in-depth qualitative interviews to con-
firm this. However, from the results reported by by Tabori et al., we conclude that the PedsQL
GI CF symptoms and concerns are important [8].
Compared to other gastro-intestinal diseases, patients with CF reported better GI QOL:
data for Crohn’s disease, ulcerative colitis, functional abdominal pain, irritable bowel syn-
drome showed values for the total PedsQL GI<80% for all conditions [22–23,32–33]. How-
ever, the data for patients with CF are skewed, as a quarter of the patients has a result <80%
and the median results for some of the subscores are comparable to other diseases. A possible
explanation for the relatively high scores in patients with CF is that they are all treated with
PERT and followed in specialized CF centres, resulting in a median, almost normal BMI
which would suggest no significant residual malabsorption [34]. From another perspective,
gastro-intestinal symptoms might not be considered very problematic by patients with CF
who have several other problems (i.e. respiratory symptoms, nasal symptoms) which is not the
case in purely gastro-intestinal diseases. This however contradicts recent patient survey results
[29].
Conclusion
In conclusion, important steps were made towards the validation of the existing PedsQL GI
for use in children with CF and we are confident that the CF PedsQL GI, its shortened version,
holds promise to be used both for clinical purposes and has potential as an outcome measure
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for clinical trials involving the gastro-intestinal aspects of CF in children. A next important
step in the validation of the CF PedsQL GI is to show response to an intervention.
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